IgG4-Related Disease: Diagnostic Methods and Therapeutic Strategies in Japan
-
- Masaki Yasufumi
- Hematology and Immunology, Kanazawa Medical University
-
- Shimizu Hironori
- Hematology and Immunology, Kanazawa Medical University
-
- Sato Nakamura Tomomi
- Hematology and Immunology, Kanazawa Medical University
-
- Nakamura Takuji
- Hematology and Immunology, Kanazawa Medical University
-
- Nakajima Akio
- Hematology and Immunology, Kanazawa Medical University
-
- Iwao Kawanami Haruka
- Hematology and Immunology, Kanazawa Medical University
-
- Miki Miyuki
- Hematology and Immunology, Kanazawa Medical University
-
- Sakai Tomoyuki
- Hematology and Immunology, Kanazawa Medical University
-
- Kawanami Takafumi
- Hematology and Immunology, Kanazawa Medical University
-
- Fujita Yoshimasa
- Hematology and Immunology, Kanazawa Medical University
-
- Tanaka Masao
- Hematology and Immunology, Kanazawa Medical University
-
- Fukushima Toshihiro
- Hematology and Immunology, Kanazawa Medical University
この論文をさがす
抄録
This review describes methods utilized in Japan to diagnose and treat patients with IgG4-related disease. A diagnosis of IgG4-related disease is based on elevated serum IgG4 concentration and an increased number of IgG4+ plasma cells. Differentiating IgG4-related disease from other disorders, especially malignancy, is quite important. Consensus treatment in Japan consists of an initial dose of prednisolone at 0.5-0.6 mg/kg/day, followed by careful and gradual dose reduction. Most patients require maintenance treatment at 5 to 10 mg/day. Patients refractory to glucocorticoids are either truly refractory or have been misdiagnosed, therefore requiring reassessment. [J Clin Exp Hematop 54(2) : 95-101, 2014]
収録刊行物
-
- Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ ａｎｄ Ｅｘｐｅｒｉｍｅｎｔａｌ Ｈｅｍａｔｏｐａｔｈｏｌｏｇｙ
-
Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ ａｎｄ Ｅｘｐｅｒｉｍｅｎｔａｌ Ｈｅｍａｔｏｐａｔｈｏｌｏｇｙ 54 (2), 95-101, 2014
日本リンパ網内系学会